Patient's question:
Hello, I would like to know: ABO blood incompatibility. Can we prevent complications before having children?Doctor's answer:
Disease Analysis: Newborn hemolytic disease caused by ABO blood type incompatibility between mother and child is called "Newborn ABO Hemolytic Disease." Over 90% of affected infants have mothers with blood type O and infants with blood type A or B. This ABO blood type incompatibility between mother and child is not uncommon in all pregnancies, accounting for about 20%. However, the occurrence of neonatal hemolytic disease is rare, occurring in only about 1/150, and the symptoms are mostly mild, often being overlooked. Only about 1/5 of the infants may develop jaundice. Over 90% of affected infants have mothers with blood type O and infants with blood type A or B. This ABO blood type incompatibility between mother and child is not uncommon in all pregnancies, accounting for about 20%. However, the occurrence of neonatal hemolytic disease is rare, occurring in only about 1/150, and the symptoms are mostly mild, often being overlooked. Only about 1/5 of the infants may develop jaundice.Guidance: ABO blood type incompatibility can lead to hemolysis, with 99% occurring in pregnant women with blood type O. It is more likely to occur when the husband has blood type A, B, or AB, and the fetus has blood type A or B. Hemolysis can cause fetal anemia, heart enlargement, liver and spleen enlargement, edema of the fetus and placenta, increased red blood cell count in the blood, and severe cases can lead to fetal hypoxia, resulting in intrauterine fetal death. Newborns may also develop jaundice, and indirect bilirubin can cross the blood-brain barrier, causing discoloration of the brain nerve nuclei and affecting intellectual development and neurological function. Therefore, prenatal blood type testing can help early identify the fetal condition and prepare for monitoring measures for neonatal hemolytic disease. Additionally, antibody titer tests should be conducted for pregnant women with blood type O. The testing schedule is as follows: the first test at 16 weeks of pregnancy, the second at 28-30 weeks of pregnancy, and then every 2-4 weeks thereafter. More than half of these pregnant women develop antibodies after 28 weeks. When the antibody titer is >1:128, it indicates a possible risk of hemolysis. Ultrasound examinations can also help detect fetal hemolysis. If fetal skin edema, pleural and abdominal effusions, liver and spleen enlargement, or placental enlargement are observed, the possibility of maternal-fetal blood type incompatibility should be considered. Of course, mothers with blood type O should not be too anxious, as not all babies of mothers with blood type O will hemolyze, and ABO hemolysis is generally mild. Careful observation of jaundice onset after birth, early diagnosis, and treatment can lead to a good prognosis. Maternal-fetal blood type incompatibility is primarily a disease caused by blood type incompatibility between the mother and fetus, which can lead to agglutination and destruction of fetal red blood cells, causing fetal or neonatal hemolytic disease.
I. Etiology The most common form of maternal-fetal blood type incompatibility is ABO blood type incompatibility, where the pregnant woman is typically blood type O and the fetus is blood type A or B, which can lead to neonatal hemolytic disease. ABO blood type incompatibility is relatively common, accounting for about 20-25% of total pregnancies, but only 2-2.5% develop hemolysis, and the symptoms are generally mild. This is because fetal tissues contain varying amounts of soluble A or B substances, which can neutralize A and B antibodies. Mild ABO hemolytic disease can be easily confused with physiological jaundice in newborns. Some cases of severe hemolytic disease progress slowly and may not reach their peak until 3-5 days after birth. Therefore, you do not need to worry too much; you can still become pregnant, but pay attention to the following issues during pregnancy and after delivery.
II. Laboratory Support Diagnosis for Suspected Blood Type Incompatibility Antibody Testing: Pregnant women with ABO incompatibility should have both partners donate blood to determine the immune anti-A or anti-B antibodies in the mother's blood against her husband's red blood cells and their titer and titer. Titer ≥1:64 is meaningful, and ≥1:512 suggests a more severe condition, requiring hospital treatment. Incomplete Antibody Testing: During early to mid-pregnancy, tests should be conducted every 1-2 months. From 28 to 32 weeks of pregnancy, tests should be performed every 2 weeks, and weekly tests should be conducted after 32 weeks of pregnancy. To enhance prenatal care, both partners should have their blood types checked before pregnancy to detect incompatibility early and prevent treatment.